Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Soon Jung | - |
dc.contributor.author | Lee, Min Young | - |
dc.contributor.author | Jo, Hyoung | - |
dc.contributor.author | Lim, Soon Sung | - |
dc.contributor.author | Jung, Sang Hoon | - |
dc.date.accessioned | 2024-01-20T15:03:29Z | - |
dc.date.available | 2024-01-20T15:03:29Z | - |
dc.date.created | 2021-09-05 | - |
dc.date.issued | 2012-04 | - |
dc.identifier.issn | 0918-6158 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/129384 | - |
dc.description.abstract | In the present study, extracts from Rhus verniciflua were demonstrated to significantly attenuate the negative effects of hydrogen peroxide (H2O2) on transformed retinal ganglion cell line (RGC-5 cells), indicating that they may be protective against oxidative stress-induced retinal degeneration. The inclusion of R. verniciflua in the culture was found to both reduce the levels of reactive oxygen species (ROS) present and lessen the up-regulation of apoptotic proteins such as cleaved poly(ADP-ribose) polymerase, cleaved caspase-3, and cleaved caspase-9. Active compounds were also successfully isolated from R. verniciflua using high-speed counter-current chromatography (HSCCC) with a two-phase solvent system composed of n-hexane ethyl acetate-methanol-water (3.5:5:3.5:5, v/v). Using this method, we successfully separated 252.1 mg of fustin at a purity of over 93.09%, 51.2 mg of fisetin at a purity of over 95.45%, 39.7 mg of sulfuretin at a purity of over 95.17%, and 10.7 mg of butein at a purity of over 95.01% from 1.5 g of R. vernicifina extract. The chemical structures of these compounds were elucidated by chemical and spectral analyses. There isolated compounds also significantly attenuated the negative effects of H2O2 on RGC-5 cells. Results therefore suggest that, due to its anti-oxidative and anti-apoptotic effects, R. verniciflua could be used as a lead substance for the treatment of retinal diseases such as glaucoma. | - |
dc.language | English | - |
dc.publisher | PHARMACEUTICAL SOC JAPAN | - |
dc.subject | GANGLION-CELL LINE | - |
dc.subject | OXIDATIVE STRESS | - |
dc.subject | IN-VIVO | - |
dc.subject | INDUCED APOPTOSIS | - |
dc.subject | EPIGALLOCATECHIN GALLATE | - |
dc.subject | LIPID-PEROXIDATION | - |
dc.subject | GLAUCOMA | - |
dc.subject | STOKES | - |
dc.subject | DEATH | - |
dc.subject | VITRO | - |
dc.title | Preparative Isolation and Purification of Neuroprotective Compounds from Rhus verniciflua by High Speed Counter-Current Chromatography | - |
dc.type | Article | - |
dc.identifier.doi | 10.1248/bpb.35.559 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | BIOLOGICAL & PHARMACEUTICAL BULLETIN, v.35, no.4, pp.559 - 567 | - |
dc.citation.title | BIOLOGICAL & PHARMACEUTICAL BULLETIN | - |
dc.citation.volume | 35 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 559 | - |
dc.citation.endPage | 567 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000302200900017 | - |
dc.identifier.scopusid | 2-s2.0-84859452692 | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | GANGLION-CELL LINE | - |
dc.subject.keywordPlus | OXIDATIVE STRESS | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | INDUCED APOPTOSIS | - |
dc.subject.keywordPlus | EPIGALLOCATECHIN GALLATE | - |
dc.subject.keywordPlus | LIPID-PEROXIDATION | - |
dc.subject.keywordPlus | GLAUCOMA | - |
dc.subject.keywordPlus | STOKES | - |
dc.subject.keywordPlus | DEATH | - |
dc.subject.keywordPlus | VITRO | - |
dc.subject.keywordAuthor | Rhus verniciflua | - |
dc.subject.keywordAuthor | neuroprotection | - |
dc.subject.keywordAuthor | high-speed counter-current chromatography | - |
dc.subject.keywordAuthor | retinal ganglion cell-5 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.